Deerfield Management Company, L.P. (Series C) Catalyst Pharmaceuticals, Inc. Call Options Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.84 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CPRX
# of Institutions
277Shares Held
95.7MCall Options Held
40.6KPut Options Held
67.2K-
Black Rock Inc. New York, NY17.7MShares$275 Million0.01% of portfolio
-
State Street Corp Boston, MA8.15MShares$126 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.98MShares$124 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.74MShares$42.4 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X02.73MShares$42.2 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $1.59B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...